These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6345112)

  • 101. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000543. PubMed ID: 32786164
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Gut microbiota-driven drug metabolism in inflammatory bowel disease.
    Crouwel F; Buiter HJC; de Boer NK
    J Crohns Colitis; 2020 Jul; 15(2):307-15. PubMed ID: 32652007
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The gut microbiome: an orchestrator of xenobiotic metabolism.
    Collins SL; Patterson AD
    Acta Pharm Sin B; 2020 Jan; 10(1):19-32. PubMed ID: 31998605
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice.
    Sun C; Chen L; Shen Z
    Saudi Pharm J; 2019 Dec; 27(8):1146-1156. PubMed ID: 31885474
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Gut microbiome interactions with drug metabolism, efficacy, and toxicity.
    Wilson ID; Nicholson JK
    Transl Res; 2017 Jan; 179():204-222. PubMed ID: 27591027
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Developing a metagenomic view of xenobiotic metabolism.
    Haiser HJ; Turnbaugh PJ
    Pharmacol Res; 2013 Mar; 69(1):21-31. PubMed ID: 22902524
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Colon targeted drug delivery systems: a review on primary and novel approaches.
    Philip AK; Philip B
    Oman Med J; 2010 Apr; 25(2):79-87. PubMed ID: 22125706
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
    Quiros JA; Heyman MB; Pohl JF; Attard TM; Pieniaszek HJ; Bortey E; Walker K; Forbes WP
    J Pediatr Gastroenterol Nutr; 2009 Nov; 49(5):571-9. PubMed ID: 19633577
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Advances in colonic drug delivery.
    Basit AW
    Drugs; 2005; 65(14):1991-2007. PubMed ID: 16162022
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
    Lowry PW; Franklin CL; Weaver AL; Szumlanski CL; Mays DC; Loftus EV; Tremaine WJ; Lipsky JJ; Weinshilboum RM; Sandborn WJ
    Gut; 2001 Nov; 49(5):656-64. PubMed ID: 11600468
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Hypersensitivity to 5-ASA suppositories.
    Borum ML; Ginsberg A
    Dig Dis Sci; 1997 May; 42(5):1076-8. PubMed ID: 9149065
    [No Abstract]   [Full Text] [Related]  

  • 116. Inflammatory bowel disease management. Some thoughts on future drug developments.
    Rhodes J; Thomas G; Evans BK
    Drugs; 1997 Feb; 53(2):189-94. PubMed ID: 9028740
    [TBL] [Abstract][Full Text] [Related]  

  • 117. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.
    Leopold CS; Friend DR
    J Pharmacokinet Biopharm; 1995 Aug; 23(4):397-406. PubMed ID: 8882747
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.
    Clerici C; Gentili G; Boschetti E; Santucci C; Aburbeh AG; Natalini B; Pellicciari R; Morelli A
    Dig Dis Sci; 1994 Dec; 39(12):2601-6. PubMed ID: 7995185
    [TBL] [Abstract][Full Text] [Related]  

  • 119. New salicylates as maintenance treatment in ulcerative colitis.
    Järnerot G
    Gut; 1994 Sep; 35(9):1155-8. PubMed ID: 7959217
    [No Abstract]   [Full Text] [Related]  

  • 120. Medical treatment of ulcerative colitis.
    Lennard-Jones JE
    Postgrad Med J; 1984 Nov; 60(709):797-802. PubMed ID: 6150475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.